Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 251 results for "Ibrutinib"

IMBRUVICA® (ibrutinib) Approved with Conditions for Relapsed ...

Oral, once-daily, single-agent therapy fills an unmet need for new treatment options to help Canadians in the fight against this deadly disease TORONTO, July 30, 2015 /CNW/ - Janssen Inc. announced today that Health Canada has issued a Notice of ... Canada NewsWire, 1 month ago

7 images for Ibrutinib

OncLive, 1 week ago
OncLive, 1 month ago
National Cancer Institute, 1 month ago
MDLinx, 1 month ago
Pharmafile, 1 month ago
MDLinx, 1 month ago
OncLive, 2 months ago

AbbVie's Imbruvica obtains European approval to treat blood cancer WM

AbbVie has received marketing approval from the European Commission (EC) for its Imbruvica (ibrutinib) to treat patients with Waldenstrom's macroglobulinemia (WM), a rare and slow-growing blood cancer. Approval was granted for the drug to treat WM ...
 Pharmaceutical Technology1 month ago AbbVie receives European approval for Humira to treat hidradenitis suppurativa  CPhI.cn1 month ago

Janssens IMBRUVICA®▼(Ibrutinib) erhält zusätzliche Zulassung der EU-Kommission für die Behandlung von Waldenströms Makroglobulinämie

Janssen's IMBRUVICA ® ▼(ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström's Macroglobulinemia Ibrutinib now the first EC-approved treatment option available for this rare B-cell lymphoma ...
 PR Newswire1 month ago

Adding Ibrutinib Is Beneficial in Previously Treated CLL

Chicago—The addition of ibrutinib reduces the risk for death or disease progression over that provided by bendamustine and rituximab (BR) alone in previously treated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), ...
 Pharmacy Practice News1 month ago European Imbruvica approval for Janssen  Pharmafile1 month ago IMBRUVICA (ibrutinib) receives additional European Commission approval for the treatment of Waldenström's Macroglobulinemia  Medical News Today1 month ago Ibrutinib recieves additional European Commission approval for the treatment of Waldenström's Macroglobulinemia  Ecancer Medicalscience1 month ago
Pharmaceutical Business Review

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie (NYSE: ABBV) announced the European Commission (EC) granted marketing authorization for IMBRUVICA ® (ibrutinib) as the first treatment option available in all 28 member states of the European Union (EU) for the treatment of ...
 News-Medical.Net1 month ago Imbruvica cleared in Europe for Waldenstrom's macroglobulinemia  Seeking Alpha1 month ago Europe clears AbbVie's Imbruvica for Waldenstrom's macroglobulinaemia  FirstWord Pharma1 month ago IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenstrom's Macroglobulinemia in Europe  Crawford Financial Planning1 month ago

CORRECTION - Janssen-Cilag International NV: Janssen's IMBRUVICA®▼ (ibrutinib) Receives Additional European..

/PRNewswire/ -- We would like to advise journalists and other readers that the news release "Janssen's IMBRUVICA®▼ (ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström's Macroglobulinemia" issued on 10 ...
 ADVFN India1 month ago

TG Therapeutics announces encouraging results from Phase II CLL study

TG-1101 also appeared to abrogate ibrutinib related lymphocytosis with patients experiencing a median 75% reduction in their absolute lymphocyte count (ALC) by the end of month 3 following initiation of combination therapy and 70% of patients ...
 Individual.com2 months ago TG Therapeutics, Inc. Announces Second Quarter 2015 Financial Results And Business Update  TheStreet.com3 weeks ago

IMBRUVICA®▼(ibrutinib) de Janssen reçoit une autre approbation donnée par la Commission européenne pour le traitement de la macroglobulinémie…

 Gnom.es1 month ago

AbbVie: IMBRUVICA Now Approved In EU To Treat Waldenstrom's Macroglobulinemia

( - AbbVie ( ABBV ) announced the European Commission has granted marketing authorization for IMBRUVICA (ibrutinib) for the treatment of Waldenstrom's macroglobulinemia, a rare, slow growing blood cancer, in adult patients who have ...
 Nasdaq1 month ago EU grants marketing approval for Imbruvica to treat Waldenstrom's macroglobulinemia  PharmaBiz1 month ago
Sys-Con Media

Study shows promise of precision medicine for most common type of lymphoma

Patients with a specific molecular subtype of diffuse large B-cell lymphoma are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease, a new
 Science Daily1 month ago The Leukemia & Lymphoma Society Applauds Encouraging Data From a Phase 2 Study of Venetoclax for a High-Risk Subset of Chronic Lymphocytic Leukemia Patients  Sys-Con Media2 weeks ago Researchers Use Precision Medicine in Common Type of Lymphoma  American Journal of Managed Care1 month ago Drug shows promise for patients with chronic lymphocytic leukemia  City of Hope2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Ibrutinib
Get updated on latest news & your favorite topics right in your inbox!
More     Less